CorMedix, Inc. (CRMD)
4.505
-0.16
(-3.53%)
USD |
NASDAQ |
Nov 18, 16:00
4.59
+0.08
(+1.89%)
After-Hours: 20:00
CorMedix Enterprise Value : 160.77M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 160.77M |
| November 16, 2026 | 172.70M |
| November 13, 2026 | 159.98M |
| November 12, 2026 | 174.28M |
| November 11, 2026 | 210.84M |
| November 10, 2026 | 216.41M |
| November 09, 2026 | 224.36M |
| November 06, 2026 | 212.43M |
| November 05, 2026 | 205.28M |
| November 04, 2026 | 239.46M |
| November 03, 2026 | 231.51M |
| November 02, 2026 | 218.00M |
| October 30, 2026 | 242.24M |
| October 29, 2026 | 396.82M |
| October 28, 2026 | 441.33M |
| October 27, 2026 | 425.43M |
| October 26, 2026 | 420.66M |
| October 23, 2026 | 413.51M |
| October 22, 2026 | 433.38M |
| October 21, 2026 | 408.74M |
| October 20, 2026 | 391.26M |
| October 19, 2026 | 376.16M |
| October 16, 2026 | 366.62M |
| October 15, 2026 | 382.51M |
| October 14, 2026 | 376.95M |
| Date | Value |
|---|---|
| October 13, 2026 | 376.95M |
| October 12, 2026 | 382.51M |
| October 09, 2026 | 376.16M |
| October 08, 2026 | 371.39M |
| October 07, 2026 | 368.21M |
| October 06, 2026 | 368.21M |
| October 05, 2026 | 366.62M |
| October 02, 2026 | 361.06M |
| October 01, 2026 | 379.34M |
| September 30, 2026 | 401.59M |
| September 29, 2026 | 503.70M |
| September 28, 2026 | 500.59M |
| September 25, 2026 | 497.49M |
| September 24, 2026 | 491.27M |
| September 23, 2026 | 485.06M |
| September 22, 2026 | 492.05M |
| September 21, 2026 | 491.27M |
| September 18, 2026 | 487.39M |
| September 17, 2026 | 492.83M |
| September 16, 2026 | 495.16M |
| September 15, 2026 | 490.50M |
| September 14, 2026 | 500.59M |
| September 11, 2026 | 495.55M |
| September 10, 2026 | 506.03M |
| September 09, 2026 | 519.23M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -54.16M |
| Eloxx Pharmaceuticals, Inc. | -8.293M |
| Breakthrough Chemistry, Inc. | -0.0298M |
| BioStem Technologies, Inc. | 17.64M |
| Cardiac Biotech Solutions, Inc. | 6.406M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.72M |
| Revenue (Quarterly) | 54.52M |
| Total Expenses (Quarterly) | 69.24M |
| EPS Diluted (Quarterly) | -0.1877 |
| Gross Profit Margin (Quarterly) | 55.03% |
| Profit Margin (Quarterly) | -27.00% |
| Earnings Yield | 14.60% |
| Operating Earnings Yield | 39.47% |
| Normalized Earnings Yield | 18.94 |